Cipla’s subsidiary - Saba Investment has entered into an agreement to sell its entire 99% equity stake in Al Jabal for Drugs and Medical Appliances Company, Yemen (AJDMA) to Khalil Ghaleb Ali Al-Jabal. The company has entered into an agreement for sale on June 7, 2017 and the transaction is expected to be closed within 35 days from Effective Date.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries.
